Edmond de Rothschild Investment Partners: Erstes Closing und Launch des Life Sciences Fonds BioDiscovery 4
Edmond de Rothschild Investment Partners is pleased to announce the first closing and launch of the fourth fund in its BioDiscovery franchise dedicated to investing in Life Sciences in France and in Europe.
Thanks to the renewed confidence of its existing institutional investor base as well as new investors who decided to participate in this new fund Edmond de Rothschild Investment Partners reached its objective of €125 million for the first closing in the expected timeframe and confirms its final objective of about €200 million by the end of the year.
Edmond de Rothschild Investment Partners will deploy the same strategy for BioDiscovery 4 as for its previous funds. The team will lead investments in 15 to 20 life science companies across all stages of development. The investments will be made both in therapeutic drug development companies and a combination of medical technology and molecular diagnostic companies. The fund will invest mainly in Europe… vollständiger Artikel (pdf)